Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist

Drug Metabolism and Disposition

Volumn 35, Issue 12, 2007, Pages 2186-2195

  Ghosal, Anima ^a   Ramanathan, Ragu ^a   Yuan, Yuan ^a   Hapangama, Neil ^a   Chowdhury, Swapan K ^a   Kishnani, Narendra S ^a   Alton, Kevin B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZAMULIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 4A11; CYTOCHROME P450 INHIBITOR; KETOCONAZOLE; MONOCLONAL ANTIBODY; O NORVICRIVIROC; QUINIDINE; RECOMBINANT ENZYME; SCH 495415; SCH 496903; SCH 643188; SCH 727390; SULFAPHENAZOLE; UNCLASSIFIED DRUG; VICRIVIROC; VICRIVIROC DERIVATIVE; VICRIVIROC HYDROXYLAMINE; VICRIVIROC N OXIDE;

ARTICLE; CONTROLLED STUDY; DEALKYLATION; DEMETHYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ANALYSIS; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BRIDGED COMPOUNDS; CARBOXYLIC ACIDS; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; ISOENZYMES; KETOCONAZOLE; KINETICS; LIVER; OXIDATION-REDUCTION; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TESTOSTERONE; TRIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 36348955045     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017517     Document Type: Article

References (23)

1. Barber CG (2004) CCR5 antagonists for the treatment of HIV. Curr Opin Investig Drugs 5:851-861.
2. Blanpain C, Libert F, Vassart G, and Parmentier M (2002) CCR5 and HIV infection. Receptors Channels 8:19-31.
3. Desai PB, Duan JZ, Zhu YW, and Kouzi S (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 23:417-424.
4. Ghosal A, Chowdhury S, Gupta S, Yuan Y, Iannucci R, Zhang H, Zbaida S, Patrick JE, and Alton KB (2005) Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 351125, a CCR5 antagonist. Xenobiotica 35:405-417.
5. Ghosal A, Hapangama N, Yuan Y, Lu X, Horne D, Patrick JE, and Zbaida S (2003) Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes, and hepatocytes. Biopharm Drug Dispos 24:375-384.
6. Ghosal A, Satoh H, Thomas PE, Bush E, and Moore D (1996) Inhibition and kinetics of cytochrome P450 3A activity in microsomes from rat, human and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
7. Gorski JC, Jones DR, Wrighton SA, Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes: contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48:173-182.
8. Heyn H, White RB, and Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948-954.
9. Hutzler JM, Hauer MJ, and Tracy TS (2001) Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos 29:1029-1034.
10. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
11. Jones DR, Christopher GJ, Hamman MA, Mayhew BS, Rider S, and Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290:1116-1125.
12. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
13. Kumar V, Rock DA, Warren CJ, Tracy TS, and Wahlstrom JL (2006) Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos 34:1903-1908.
14. Masimirembwa CM, Otter C, Berg M, Jonsson M, Leidvik B, Jonsson E, Johansson T, Backman A, Edlund A, and Andersson TB (1999) Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab Dispos 27:1117-1122.
15. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
16. Newton DJ, Wang RW, and Lu AYH (1995) Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
17. Ramanathan R, Chowdhury SK, and Alton KB (2005a) Oxidative metabolites of drugs and xenobiotics: LC-MS methods to identify and characterize in biological matrices, in Identification and Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC-MS in from Biological Matrices (Chowdhury SK ed), pp 225-276, Elsevier BV, Amsterdam, The Netherlands.
18. Ramanathan R, Su AD, Alvarez N, Blumenkrantz N, Chowdhury SK, Alton KB, and Patrick JE (2000) Liquid chromatography/mass spectrometry methods for distinguishing N-oxides from hydroxylated compounds. Anal Chem 72:1352-1359.
19. Ramanathan R, Zhong R, Alvarez N, Kennedy C, Grotz D, Rindgen D, Cox K, Chowdhury S, Wirth M, and Alton K (2005b) Comparative metabolism and excretion of a novel CCR5 receptor antagonist, SCH 417690 (vicriviroc), in human, monkey, and rat. Drug Metab Rev 37:725-726.
20. Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JCL, et al. (2004) Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab Dispos 32:105-112.
21. Tong W, Chowdhury SK, Chen JC, Zhong R, Alton KB, and Patrick JE (2001) Fragmentation of N-oxides (deoxygenation) in atmospheric pressure ionization: investigation of the activation process. Rapid Commun Mass Spectrom 15: 2085-2090.
22. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxymidazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharmacol Res 11:921-924.
23. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, and Yokoi T (1999) Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27:1260-1266.